ORMP Oramed Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORMP

Price (delayed)

$2.34

Market cap

$94.81M

P/E Ratio

16.71

Dividend/share

N/A

EPS

$0.14

Enterprise value

$137.38M

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and ...

Highlights
The EPS has surged by 134% since the previous quarter and by 115% year-on-year
The net income has soared by 134% QoQ and by 115% YoY
Oramed Pharmaceuticals's quick ratio has shrunk by 89% YoY but it has increased by 36% QoQ
The gross profit has plunged by 50% YoY and by 34% from the previous quarter
The revenue has dropped by 50% year-on-year and by 34% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oramed.com
Peers: PLX RARE LXRX

Key stats

What are the main financial stats of ORMP
Market
Shares outstanding
40.52M
Market cap
$94.81M
Enterprise value
$137.38M
Valuations
Price to earnings (P/E)
16.71
Price to book (P/B)
0.58
Price to sales (P/S)
70.4
EV/EBIT
18.17
EV/EBITDA
17.71
EV/Sales
102.52
Earnings
Revenue
$1.34M
EBIT
$7.56M
EBITDA
$7.76M
Free cash flow
-$10.55M
Per share
EPS
$0.14
Free cash flow per share
-$0.26
Book value per share
$4.06
Revenue per share
$0.03
TBVPS
$5.47
Balance sheet
Total assets
$220.55M
Total liabilities
$57.66M
Debt
$51.62M
Equity
$163.82M
Working capital
$109.37M
Liquidity
Debt to equity
0.32
Current ratio
3.06
Quick ratio
3.05
Net debt/EBITDA
5.49
Margins
EBITDA margin
579%
Gross margin
100%
Net margin
412.3%
Operating margin
-1,176.8%
Efficiency
Return on assets
2.9%
Return on equity
3.6%
Return on invested capital
4.2%
Return on capital employed
4.5%
Return on sales
564.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORMP stock price

How has the Oramed Pharmaceuticals stock price performed over time
Intraday
0%
1 week
1.74%
1 month
-16.43%
1 year
-10.34%
YTD
1.3%
QTD
-19.86%

Financial performance

How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$1.34M
Gross profit
$1.34M
Operating income
-$15.77M
Net income
$5.53M
Gross margin
100%
Net margin
412.3%
ORMP's net margin has soared by 151% QoQ and by 130% YoY
The net income has soared by 134% QoQ and by 115% YoY
The operating income has surged by 61% year-on-year and by 27% since the previous quarter
The gross profit has plunged by 50% YoY and by 34% from the previous quarter

Growth

What is Oramed Pharmaceuticals's growth rate over time

Valuation

What is Oramed Pharmaceuticals stock price valuation
P/E
16.71
P/B
0.58
P/S
70.4
EV/EBIT
18.17
EV/EBITDA
17.71
EV/Sales
102.52
The EPS has surged by 134% since the previous quarter and by 115% year-on-year
The P/B is 76% less than the 5-year quarterly average of 2.4 and 17% less than the last 4 quarters average of 0.7
The equity has grown by 10% from the previous quarter and by 8% YoY
The revenue has dropped by 50% year-on-year and by 34% since the previous quarter
The stock's price to sales (P/S) is 36% more than its last 4 quarters average of 51.8 but 4.6% less than its 5-year quarterly average of 73.8

Efficiency

How efficient is Oramed Pharmaceuticals business performance
The return on sales has surged by 163% since the previous quarter and by 142% year-on-year
The company's return on invested capital has surged by 136% QoQ and by 115% YoY
The ROE has soared by 133% from the previous quarter and by 115% YoY
The ROA has soared by 132% since the previous quarter and by 113% year-on-year

Dividends

What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORMP.

Financial health

How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's quick ratio has shrunk by 89% YoY but it has increased by 36% QoQ
ORMP's current ratio has dropped by 89% year-on-year but it is up by 36% since the previous quarter
ORMP's debt is 68% lower than its equity
Oramed Pharmaceuticals's debt to equity has decreased by 37% QoQ
ORMP's debt is down by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.